BioTuesdays

Giving healthcare companies and their stories the exposure they deserve.

Subscribe

THIS WEEK'S FEATURE

MORE FEATURES

BriaCell breast cancer program ready for partnering

Dr. Bill Williams, President and CEO BriaCell Therapeutics (OTCQB:BCTXD; TSXV:BCT) believes its Phase 2 clinical program in advanced breast cancer, which includes an ongoing combination study of its Bria-IMT with immune...


NEWS

Dawson James ups CollPlant PT to $15 from $9

Dawson James Securities raised its price target for CollPlant Biotechnologies (NASDAQ:CLGN) to $15 from $9, reflecting an “increase in valuation, which translates into less dilution in terms of our assumptions around...

AGP ups Itamar Medical PT to $19.50 from $15.50

Alliance Global Partners raised its price target for Itamar Medical (NASDAQ:ITMR) to $19.50 from $15.50, reflecting preliminary fourth quarter revenue results, 2020 guidance and a recent meeting with the company’s...

Ladenburg starts ArTara Therapeutics at buy; PT $45

Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...

Echelon starts Protech Home Medical at buy; PT $2.50

Echelon Wealth Partners launched overage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $2.50. The stock closed at 91 cents on Jan. 22. “We believe the firm is well positioned within [the...

HCW lowers Capricor Therapeutics PT to $9

H.C. Wainwright lowered its price target for Capricor Therapeutics (NASDAQ:CAPR) to $9.50 based on a higher fully diluted share count but maintained its “buy” rating. The stock closed at $1.83 on Jan. 17. Analyst Joseph...


Just a few of the companies we’ve highlighted along the way

coverage

Subscribe

Sign up to our weekly BioTuesdays newsletter.